Intensity Therapeutics Inc. (INTS)
NASDAQ (CM) NASDAQ (CM) Primary Summary
INTS Chart
Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's Why
Intensity Therapeutics Inc. (INTS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Intensity Therapeutics Inc. (INTS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's What You Should Know
Intensity Therapeutics Inc. (INTS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Intensity Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| MR Maximiliaan Rijkenberg SAPIENT CAPITAL LLC | 26,006 | $152,915 | $121,187.96 | -$31,727.04 | -20.75% |
Intensity Therapeutics Inc. (INTS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Intensity Therapeutics Inc. ever had a stock split?
Intensity Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Lewis H. Bender CEO | NASDAQ (CM) Exchange | 45828J202 CUSIP |
| US Country | 16 Employees | - Last Dividend | 19 Feb 2026 Last Split | 30 Jun 2023 IPO Date |
Overview
Intensity Therapeutics, Inc. is a cutting-edge clinical-stage biotechnology company specializing in oncology, with a primary focus on inventing, developing, and commercializing cancer treatments. Founded in 2012 and based in Shelton, Connecticut, the company is at the forefront of battling cancer through innovative drug development strategies with a mission to extend lives and improve patient outcomes.
Products and Services
- INT230-6 for Refractory Solid Tumors
INT230-6 is Intensity Therapeutics’ flagship product candidate, currently in clinical trials for the treatment of various refractory solid tumors. Specifically, it is in Phase 3 trials for the treatment of soft tissue sarcoma, a type of cancer that arises from soft tissues like fat, muscles, nerves, and blood vessels. This advanced phase demonstrates significant progress in the drug’s development journey, highlighting its potential efficacy and safety profile for patients suffering from this challenging condition.
- INT230-6 for Neoadjuvant and Metastatic Triple Negative Breast Cancer
This formulation of INT230-6 is being evaluated in Phase 2 clinical trials for its effectiveness against neoadjuvant and metastatic triple-negative breast cancer (TNBC). TNBC is a particularly aggressive form of breast cancer that lacks three commonly found receptors known to fuel most breast cancer growth—estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). Due to the absence of these receptors, TNBC is harder to treat, making INT230-6’s progress in this area a significant step toward offering hope to patients dealing with this difficult diagnosis.
